研究

Haeno T, Sakai K, Minamoto S, Nakatsu D, De Velasco MA, Rai S, Tanaka H, Matsumura I, Nishio K.

Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse Large B-Cell Lymphoma

Kashima Y, Takaya H, Miyagawa C, Otani T, Sakai K, Nishio K, Matsumura N.

A case of endometrioid carcinoma of the endometrium that progressed to lethal neuroendocrine carcinoma as a result of TMEM178B-BRAF fusion

Fukuda N, Takashima T, Nakai H, Yoshioka E, Ito K, Taniguchi R, Tsubamoto H, Motohashi T, Fujiwara S, Katsuda T, Nishio S, Nagano H, Nishikawa R, Kai K, Arakawa A, Sakai K, Morii E, Nishio K, Matsumura N.

Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s)

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K.

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

Kurosaki T, Suzuki S, Yonesaka K, Kawanaka Y, Takehara T, Teramura T, Sakai K, Nishio K, Hayashi H.

Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression

Kajiyama H, Kashima Y, Otani T, Sakai K, Shiraishi N, Nishio K, Shishido-Hara Y, Ito A, Minamiguchi S, Matsumura N.

Ovarian Epithelioid Tumor With FUS::CREM Fusion in a 63-Year-Old Woman: A Case Report of an Emerging Entity Associated With Systemic Inflammation

Sumitomo M, Kotani Y, Murakami K, Abiko K, Sakai K, Otani T, Ueda A, Ukita M, Taga A, Emoto I, Sekiyama K, Okudate M, Matsubara M, Yamanishi Y, Nishio K, Mandai M, Matsumura N.

Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study

Kawanaka Y, Yonesaka K, Tanizaki J, Maenishi O, Sakai K, Kakimi K, Nishio K, Hayashi H.

Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody

Nishino K, Seto T, Nishio M, Nishio K, Kasahara K, Satouchi M, Yoh K, Hayashi H, Enatsu S, Matsui T, Varughese SC, Visseren-Grul C, Nakagawa K.

RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC

Saito Y, Adomi S, Sakai K, Antonio De Velasco M, Hashimoto M, Banno E, Hayashi Y, Minami T, Nishio K, Fujita K.

Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Non-muscle-Invasive Bladder Cancer

Iwama E, Sakai K, Harada T, Kanda S, Sugawara S, Yokoyama T, Taniguchi H, Tanaka K, Toyozawa R, Koyama K, Zenke Y, Kida G, Nishioka Y, Yokouchi H, Hirose M, Nishio K, Yamamoto N, Ohe Y, Okamoto I.

Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations

Nagashima H, Fukuhara T, Utsumi Y, Suzuki A, Miyanaga A, Seike M, Azuma K, Asahina H, Kisohara A, Kawashima Y, Tanaka H, Kanemaru R, Miyauchi E, Furuya N, Sato H, Nakashima K, Watanabe S, Sakai K, Nishio K, Takahashi F, Kobayashi K, Maemondo M.

A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study

Oiki H, Suda K, Hamada A, Fujino T, Obata K, Kobayashi Y, Sakai K, Fukuda S, Ohara S, Ito M, Soh J, Nishio K, Mitsudomi T, Tsutani Y.

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study